109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
蛋白质组学分析发现 CDH2 可作为打鼾人群中非酒精性脂肪肝及肝纤维化的潜在筛查标志物
Authors Huang S, Deng X, Chen J, Huang J , Xie H, Wang B, Lian N
Received 29 April 2025
Accepted for publication 23 September 2025
Published 14 October 2025 Volume 2025:17 Pages 2669—2680
DOI https://doi.org/10.2147/NSS.S532717
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Marco Veneruso
Shiyuan Huang,1,2,* Xiaoyu Deng,1,2,* Jia Chen,1,2 Jiefeng Huang,1,2 Hansheng Xie,1,2 Biying Wang,1,2 Ningfang Lian1,2
1Department of Respiratory and Critical Care Medicine, Respiratory Disease Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, People’s Republic of China; 2Department of Respiratory and Critical Care Medicine, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, 350005, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ningfang Lian, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, People’s Republic of China, Tel +86-591-87981698, Email lotusnf@fjmu.edu.cn
Purpose: Snoring individuals, particularly those with obstructive sleep apnea (OSA), exhibit a higher prevalence of nonalcoholic fatty liver disease (NAFLD) and liver fibrosis. The objectives of this study were to explore potential screening biomarkers for NAFLD and liver fibrosis in the snoring population.
Methods: The research was carried out as a cross-sectional study at the Sleep Center of the First Affiliated Hospital of Fujian Medical University. All patients underwent FibroScan and overnight polysomnography (PSG). The 96-metabolism related proteins were detected using liquid chromatography-high resolution mass spectrometry (Oink Proteomics).
Results: A total of 59 NAFLD were found among the 87 snoring patients. A total of 12 proteins with differential expression levels were identified between non-NAFLD group and NAFLD group via Oink Proteomics. The correlation analysis revealed a close correlation between Cadherin 2 (CDH2) and NAFLD, liver fibrosis (with correlation coefficients of 0.394 and 0.383, respectively, both P < 0.05). The risk of NAFLD and liver fibrosis was much higher in snorers with higher levels of CHD2 compared with snorers with lower levels of CHD2 (both P < 0.05). A combination of CHD2, age, BMI, glucose, AHI and waistline presented the acceptable AUC for the detection of NAFLD and liver fibrosis in snoring patients (0.92, 95% CI: 0.86– 0.98 and 0.81, 95% CI: 0.72– 0.91, respectively, both p < 0.001).
Conclusion: In snoring patients, higher level of CDH2 was identified as a risk factor for NAFLD and liver fibrosis; a combination of CDH2, age, BMI, glucose, AHI and waistline could act as a convenient and effective indicator for screening NAFLD and liver fibrosis. Future research should expand the sample size and conduct multicenter validation to further explore the value of CDH2.
Plain Language Summary: Snoring individuals have an elevated incidence of nonalcoholic fatty liver disease (NAFLD) and liver fibrosis. Oink Proteomics discovered that CDH2 expression was upregulated in individuals with snoring who also have NAFLD. Further analysis revealed that a combination of CDH2, age, Body mass index (BMI), glucose, Apnea hypopnea index (AHI) and waistline could act as a convenient and effective indicator for screening NAFLD and liver fibrosis in snoring patients.
Keywords: obstructive sleep apnea, nonalcoholic fatty liver disease, liver fibrosis, biomarkers, proteome profiling
1Department of Respiratory and Critical Care Medicine, Respiratory Disease Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, People’s Republic of China; 2Department of Respiratory and Critical Care Medicine, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, 350005, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ningfang Lian, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, People’s Republic of China, Tel +86-591-87981698, Email lotusnf@fjmu.edu.cn
Purpose: Snoring individuals, particularly those with obstructive sleep apnea (OSA), exhibit a higher prevalence of nonalcoholic fatty liver disease (NAFLD) and liver fibrosis. The objectives of this study were to explore potential screening biomarkers for NAFLD and liver fibrosis in the snoring population.
Methods: The research was carried out as a cross-sectional study at the Sleep Center of the First Affiliated Hospital of Fujian Medical University. All patients underwent FibroScan and overnight polysomnography (PSG). The 96-metabolism related proteins were detected using liquid chromatography-high resolution mass spectrometry (Oink Proteomics).
Results: A total of 59 NAFLD were found among the 87 snoring patients. A total of 12 proteins with differential expression levels were identified between non-NAFLD group and NAFLD group via Oink Proteomics. The correlation analysis revealed a close correlation between Cadherin 2 (CDH2) and NAFLD, liver fibrosis (with correlation coefficients of 0.394 and 0.383, respectively, both P < 0.05). The risk of NAFLD and liver fibrosis was much higher in snorers with higher levels of CHD2 compared with snorers with lower levels of CHD2 (both P < 0.05). A combination of CHD2, age, BMI, glucose, AHI and waistline presented the acceptable AUC for the detection of NAFLD and liver fibrosis in snoring patients (0.92, 95% CI: 0.86– 0.98 and 0.81, 95% CI: 0.72– 0.91, respectively, both p < 0.001).
Conclusion: In snoring patients, higher level of CDH2 was identified as a risk factor for NAFLD and liver fibrosis; a combination of CDH2, age, BMI, glucose, AHI and waistline could act as a convenient and effective indicator for screening NAFLD and liver fibrosis. Future research should expand the sample size and conduct multicenter validation to further explore the value of CDH2.
Plain Language Summary: Snoring individuals have an elevated incidence of nonalcoholic fatty liver disease (NAFLD) and liver fibrosis. Oink Proteomics discovered that CDH2 expression was upregulated in individuals with snoring who also have NAFLD. Further analysis revealed that a combination of CDH2, age, Body mass index (BMI), glucose, Apnea hypopnea index (AHI) and waistline could act as a convenient and effective indicator for screening NAFLD and liver fibrosis in snoring patients.
Keywords: obstructive sleep apnea, nonalcoholic fatty liver disease, liver fibrosis, biomarkers, proteome profiling